Theriva Biologics (TOVX): Company Future Sales Volume

Graphic logo of Theriva Biologics (TOVX)

The development of Theriva Biologics, Inc. (TOVX) is independent of GDP, relying instead on test results. The organization's promising sales volume confirms this trend, where 0.00 indicates the current level. Theriva Biologics, Inc. (TOVX) is seeking ways to expose tumors to the immune system using proprietary adenoviruses. High scientific barriers protect the business, although prolonged licensing temporarily limits final profits.

Company Revenue Forecast: Theriva Biologics, Inc. (TOVX) for 04/28/2023 - 11/18/2026

TOVX (Theriva Biologics, Inc.): analytical breakdowns and indicator data

- stock value and consensus price forecast:
Summary company analysis:Theriva Biologics
Product sample of Theriva Corp

The investment attractiveness of Theriva Biologics, Inc. (TOVX) depends on the success of clinical trials in oncology. This indicator reflects the real-time market consensus regarding future cash inflows from product commercialization. By analyzing the company's projected sales volumes, an investor can see the trend of expected trading turnover. For a company without commercial sales, this chart reveals stagnation risks and the unattainability of target metrics. This metric allows for the timely identification of a value trap.

Direct competitors

Company Projected Revenue ImmunityBio Inc (IBRX)|Company Future Sales Volume Immunocore PLC IMCR|Janux Therapeutics Inc - Company Future Sales Volume|Projected Sales Volume Arcus Corp RCUS|ZYME - Company Projected Revenue|TNGX (tangotx.com) - Company Revenue Forecast|Iovance Corp (IOVA) - Company Projected Revenue|Company Expected Sales Volume Immatics Corp (IMTX)|Company Future Sales Volume XNCR|CMPX - Company Sales Forecast|Company Future Sales Volume REPL (Replimune Corp)|Company Projected Revenue Volume LYEL|Projected Sales Volume IPHA (Innate Pharma)|Company Future Revenue PYXS|Compugen Limited - Projected Sales Volume|Company Expected Sales Volume IO Biotech Inc.|Sutro Biopharma, Inc. (STRO) - Company Projected Revenue|MiNK Therapeutics, Inc. - Company Future Revenue|HOWL (Werewolf) - Projected Sales Volume|Projected Sales Volume immixbio.com|Company Projected Revenue ALX Oncology Holdings (ALXO)|CUE - Company Expected Sales Volume|PDS Biotechnology Corporation - Company Future Sales Volume|Sonnet BioTherapeutics (SONN) - Company Expected Sales Volume|MAIA - Company Projected Revenue|LIMN: Company Projected Revenue|LVTX: Projected Sales Volume|Company Expected Sales Volume NextCure, Inc. (NXTC)|LPTX (Leap Tx) - Projected Sales Volume|INTS (Intensity Therapeutics) - Company Projected Revenue Volume|Company Projected Revenue Sensei Bio (SNSE)|Company Projected Revenue Volume GRTS|Kineta Bio - Company Future Sales Volume|NEXI - Company Future Sales Volume|TSBX: Company Future Sales Volume|VCNX (Vaccinex, Inc.) - Company Revenue Forecast|Harpoon Tx (HARP) - Company Projected Revenue